Chemical approaches to control gene expression

Gene Expression

Volumn 9, Issue 1-2, 2000, Pages 77-91

  Gottesfeld, J M ^a   Turner, J M ^a   Dervan, P B ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b California Institute of Technology   (United States)

Author keywords

Gene transcription; Molecular medicine; Novel therapies; Therapeutic strategies

Indexed keywords

DNA; MESSENGER RNA;

GENE EXPRESSION REGULATION; GENE REPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; RNA PROCESSING; TRANSLATION REGULATION;

BACTERIA (MICROORGANISMS);

EID: 0033710231     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000001783992696     Document Type: Review

References (78)

1. Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks
2. Distamycin A tallimustine inhibit TBP binding and basal in vitro transcription
3. Targeting of the Sp1 binding sites of HIV-1 long terminal repeat with chromomycin. Disruption of nuclear factor. DNA complexes and inhibition of in vitro transcription
4. TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation
5. Catalytic DNA: In training and seeking employment
6. Inhibition of major-groove-binding proteins by pyrrole-imidazole polyamides with an Arg-Pro-Arg positive patch
7. A microgonotropen branched decaaza decabutylamine and its DNA and DNA/transcription factor interactions
8. A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression
9. Targeting E2F1-DNA complexes with microgonotropen DNA binding agents
10. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA
11. Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter
12. Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers
13. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence
14. Definition of the binding sites of individual zinc fingers in the transcription factor IIIA-5 S RNA gene complex
15. Making drugs out of oligonucleotides: A brief review and perspective
16. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase
17. Small-molecule-based strategies for controlling gene expression
18. Sequence-specific DNA recognition by polyamides
19. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands
20. Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kB, and DNA by a designed DNA-binding ligand
21. Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides
22. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain
23. Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication
24. Antisense oligonucleotides as therapeutic agents
25. Design of a G. C-specific DNA minor groove-binding peptide
26. Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist
27. Functional analysis of DNA bending and unwinding by the high mobility group domain of LEF-1
28. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA
29. Regulation of gene expression by small molecules
30. Inhibition of gene expression by anti-sense C-5 propyne oligonucleotides detected by a reporter enzyme
31. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition
32. Perturbing the DNA sequence selectivity of metallointercalator-peptide conjugates by single amino acid modification
33. TBP a universal eukaryotic transcription factor?
34. Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: A paradigm for the development of transcriptional antagonists
35. Inhibition of gene expression in human cells through small molecule-RNA interactions
36. Structural basis for GC recognition in the DNA minor groove
37. Structural effects of DNA sequence on T. A recognition by hydroxypyrrole/pyrrole pairs in the minor groove
38. Structure of a photoactive rhodium complex intercalated into DNA
39. A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA
40. Co-crystal structure of TBP recognizing the minor groove of a TATA element
41. Transcriptional repression by zinc finger peptides. Exploring the potential for applications in gene therapy
42. Crystal structure of a yeast TBP/TATA-box complex
43. Doxorubicin represses the function of the myogenic helix-loophelix transcription factor MyoD. Involvement of Id gene induction
44. Selection and characterization of an RNA decoy for transcription factor NF-kappa B
45. The Tax protein-DNA interaction is essential for HTLV-I transactivation in vitro
46. Sequence-selective carbohydrate-DNA interaction: Dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function
47. Double duplex invasion by peptide nucleic acid: A general principle for sequence-specific targeting of double-stranded DNA
48. Structural basis for DNA bending by the architectural transcription factor LEF-1
49. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro
50. Activation of gene expression by small molecule transcription factors
51. Inhibitors of protein-RNA complexation that target the RNA: Specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules
52. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter
53. Importance of minor groove binding zinc fingers within the transcription factor IIIA DNA complex
54. Transcriptional activation by artificial recruitment in mammalian cells
55. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis
56. Peptide nucleic acids as therapeutic agents
57. Evidence that a minor groove-binding peptide and a major groove-binding protein can simultaneously occupy a common site on DNA
58. Site-specific inhibition of transcription factor binding to DNA by a metallointercalator
59. Targeting sites within HIV-1 cDNA with a DNA-cleaving ribozyme
60. Controlling gene expression using synthetic ligands
61. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells
62. A general purpose RNA-cleaving DNA enzyme
63. Synthesis and screening of small molecule libraries active in binding to DNA
64. Interaction of calicheamicin gamma1(I) and its related carbohydrates with DNA-protein complexes
65. The enediyne antibiotics
66. Nucleic acid molecular switches
67. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme
68. The anti-cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation
69. Subnanomolar sequence-specific recognition in the minor groove of DNA by designed ligands
70. Targeting DNA-binding drugs to sequence-specific transcription factor. DNA complexes. Differential effects of intercalating and minor groove binding drugs
71. Targeting the minor groove of DNA
72. Controlling gene expression in living cells through small molecule-RNA interactions
73. Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands
74. Asymmetric DNA binding by a homodimeric bHLH protein
75. Multiprotein-DNA complexes in transcriptional regulation
76. Design of a triple-helix-specific cleaving reagent
77. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production
78. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds